AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca is currently recruiting participants for a Phase III study titled ‘A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2’. The study aims to evaluate the efficacy and safety of AZD0901 as a second or later-line treatment for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing CLDN18.2.
The intervention being tested is AZD0901, an experimental drug administered via intravenous infusion. It is compared against the investigator’s choice of therapy, which includes various regionally accepted chemotherapies or targeted therapies.
The study follows an interventional design with randomized allocation and a parallel intervention model. It is open-label but sponsor-blinded, with single masking for outcomes assessors. The primary purpose of the study is treatment-focused.
The study officially started on March 4, 2024, with the last update submitted on July 1, 2025. These dates are crucial as they mark the progression and current status of the study, indicating ongoing recruitment and data collection.
This clinical study update could potentially influence AstraZeneca’s stock performance positively, as successful results may enhance investor confidence and market position, especially in the competitive oncology sector. The study’s outcome could also impact the competitive landscape, particularly for companies developing similar therapies.
The study is ongoing, and further details are available on the ClinicalTrials portal.